Sotera Health Company (SHC) stock analysis

Healthcare · Diagnostics & Research

From the 10-K filed 2026-02-24

Business type: Capital compounder

How it makes money

It earns revenue by providing essential terminal sterilization, lab testing, and advisory services that medical, pharmaceutical, and food product manufacturers need to meet government regulations.

It operates across three reportable segments: Sterigenics, Nordion, and Nelson Labs. For the year ended December 31, 2025, it achieved net revenues of $1,163.6 million, driven by sustained favorability in pricing and volume/mix.

Customers pay because these sterilization and testing services are a mandatory last step in manufacturing before products reach healthcare practitioners and patients. Most of these services are necessary for customers to satisfy applicable government requirements.

What protects it: the moat

It protects its market position through deep regulatory expertise, longstanding customer relationships, and its status as the only vertically integrated global gamma sterilization provider.

Management claims that its industry-recognized scientific and technological expertise, along with facilities strategically located near customer manufacturing sites, helps ensure regulatory compliance and safety. Furthermore, the combination of its Sterigenics terminal sterilization business and its Nordion Co-60 supply business makes it the only vertically integrated global gamma sterilization provider in the industry.

What growth costs

It continuously reinvests through active capacity expansion projects, Co-60 development initiatives, lab expansions, and disciplined strategic acquisitions.

To maintain and grow its earnings, it advances growth-related investments across its segments, including active capacity expansion projects within the Sterigenics segment, Co-60 development projects in the Nordion segment, and lab expansion efforts to support pharma testing services in the Nelson Labs segment. It also remains committed to a disciplined acquisition strategy.

What could damage it

A disruption in the supply of key materials like EO or Co-60 could significantly impair operations and financial results.

Because it relies on specific materials and resources such as ethylene oxide and Cobalt-60 to operate its sterilization facilities, any supply chain disruption or significant price increase in these direct materials—stemming from geopolitical instability or sanctions—would directly constrain its ability to provide services, thereby harming operating results.

About Sotera Health Company

Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Other companies in Diagnostics & Research